Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma

Published:2022-10 Issue: Volume:Volume 9 Page:1065-1079
ISSN:2253-5969
Container-title:Journal of Hepatocellular Carcinoma
language:en
Short-container-title:JHC

Author:

Kaseb Ahmed O,Guan Yinghui,Gok Yavuz Betul,Abbas Alexander R,Lu Shan,Hasanov Elshad^ORCID,Toh Han Chong,Verret Wendy,Wang Yulei^ORCID

Publisher

Informa UK Limited

Subject

General Medicine

Reference17 articles.

1. Predicting the prognosis of chronic liver disease: An evolution from child to MELD

2. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics

3. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement

4. Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD

5. Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of angiogenesis in tumour;Frontiers in Oncology;2024-03-25

2. Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma;Journal of Hepatocellular Carcinoma;2023-10

3. Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma;International Journal of Molecular Sciences;2023-07-22

4. Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights;Journal of Hepatocellular Carcinoma;2023-07

5. Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future;European Journal of Cell Biology;2023-03